Your browser doesn't support javascript.
loading
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree, Alison C; Ostler, Peter; van der Voet, Hans; Chu, William; Loblaw, Andrew; Ford, Daniel; Tolan, Shaun; Jain, Suneil; Martin, Alexander; Staffurth, John; Armstrong, John; Camilleri, Philip; Kancherla, Kiran; Frew, John; Chan, Andrew; Dayes, Ian S; Duffton, Aileen; Brand, Douglas H; Henderson, Daniel; Morrison, Kirsty; Brown, Stephanie; Pugh, Julia; Burnett, Stephanie; Mahmud, Muneeb; Hinder, Victoria; Naismith, Olivia; Hall, Emma; van As, Nicholas.
Afiliação
  • Tree AC; The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK. Electronic address: alison.tree@icr.ac.uk.
  • Ostler P; Mount Vernon Cancer Centre, Northwood, UK.
  • van der Voet H; The James Cook University Hospital, Middlesbrough, UK.
  • Chu W; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Loblaw A; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Ford D; University Hospitals Birmingham, Birmingham, UK.
  • Tolan S; The Clatterbridge Cancer Centre, Liverpool, UK.
  • Jain S; Queen's University Belfast, Belfast, UK.
  • Martin A; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Staffurth J; Cardiff University, Cardiff, UK.
  • Armstrong J; Cancer Trials Ireland, Dublin, Ireland; St Luke's Radiation Oncology Network, St Lukes Hospital, Dublin, Ireland.
  • Camilleri P; Churchill Hospital, Oxford, UK.
  • Kancherla K; University Hospitals of Leicester, Leicester, UK.
  • Frew J; Freeman Hospital, Newcastle, UK.
  • Chan A; University Hospitals Coventry & Warwickshire, Coventry, UK.
  • Dayes IS; Department of Oncology, McMaster University, Hamilton, ON, Canada.
  • Duffton A; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Brand DH; The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.
  • Henderson D; University Hospitals Birmingham, Birmingham, UK.
  • Morrison K; The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.
  • Brown S; The Institute of Cancer Research, London, UK.
  • Pugh J; The Institute of Cancer Research, London, UK.
  • Burnett S; The Institute of Cancer Research, London, UK.
  • Mahmud M; The Institute of Cancer Research, London, UK.
  • Hinder V; The Institute of Cancer Research, London, UK.
  • Naismith O; The Royal Marsden Hospital, London, UK; Radiotherapy Trials QA Group, London, UK.
  • Hall E; The Institute of Cancer Research, London, UK.
  • van As N; The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.
Lancet Oncol ; 23(10): 1308-1320, 2022 10.
Article em En | MEDLINE | ID: mdl-36113498
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Radiocirurgia / Radioterapia de Intensidade Modulada Tipo de estudo: Clinical_trials / Guideline Limite: Humans / Male Idioma: En Revista: Lancet Oncol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Radiocirurgia / Radioterapia de Intensidade Modulada Tipo de estudo: Clinical_trials / Guideline Limite: Humans / Male Idioma: En Revista: Lancet Oncol Ano de publicação: 2022 Tipo de documento: Article